Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20731
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNg, Zi Yun-
dc.contributor.authorBishton, Mark-
dc.contributor.authorRitchie, David-
dc.contributor.authorCampbell, Robert-
dc.contributor.authorGilbertson, Michael-
dc.contributor.authorHill, Kate-
dc.contributor.authorRatnasingam, Sumita-
dc.contributor.authorSchwarer, Anthony-
dc.contributor.authorManos, Kate-
dc.contributor.authorShorten, Sophie-
dc.contributor.authorNg, Melissa-
dc.contributor.authorNelson, Niles-
dc.contributor.authorXin, Liu-
dc.contributor.authorDe Mel Widanalage, Sanjay-
dc.contributor.authorSunny, Tenny-
dc.contributor.authorPurtill, Duncan-
dc.contributor.authorPoon, Michelle-
dc.contributor.authorJohnston, Anna-
dc.contributor.authorCochrane, Tara-
dc.contributor.authorLee, Hui-Peng-
dc.contributor.authorHapgood, Greg-
dc.contributor.authorTam, Constantine-
dc.contributor.authorOpat, Stephen-
dc.contributor.authorHawkes, Eliza-
dc.contributor.authorSeymour, John-
dc.contributor.authorCheah, Chan Yoon-
dc.date2019-04-15-
dc.date.accessioned2019-04-30T23:55:29Z-
dc.date.available2019-04-30T23:55:29Z-
dc.date.issued2019-08-
dc.identifier.citationHematological oncology 2019; 37(3): 253-260-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20731-
dc.description.abstractMantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant eligible patients and the optimal approach remains unknown. We performed an international, retrospective study of transplant eligible patients to assess impact of induction chemo-immunotherapy and conditioning regimens on clinical outcomes. We identified 228 patients meeting inclusion criteria. Baseline characteristics were similar among the induction groups except for some variation in age. The type of induction chemo-immunotherapy received did not influence overall response rates (ORR) (0.43), progression free survival (PFS) (P>0.67) or overall survival (OS) (P>0.35) on multivariate analysis (PFS and OS). Delivery of ASCT was associated with favourable PFS and OS (0.01) on univariate analysis only; this benefit was not seen on multivariate analysis - PFS (0.36) and OS (0.21). Compared with BuMel (busulfan and melphalan), the use of the BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning regimen was associated with inferior PFS (HR=2.0 [95%CI 1.1-3.6], 0.02) but not OS (HR=1.1 [95%CI 0.5-2.3] 0.81) on univariate analysis only. Within the limits of a retrospective study and modest power for some comparisons, type of induction therapy did not influence ORR, PFS or OS for transplant eligible patients with MCL. International efforts are required to perform randomized clinical trials evaluating chemo-immunotherapy induction regimens.-
dc.language.isoeng-
dc.subjectAutologous Stem Cell Transplant-
dc.subjectConditioning-
dc.subjectInduction-
dc.subjectMantle Cell Lymphoma-
dc.titleA Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma.-
dc.typeJournal Article-
dc.identifier.journaltitleHematological oncology-
dc.identifier.affiliationDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia-
dc.identifier.affiliationDepartment of Haematology, Royal Melbourne Hospital & Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Box Hill, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology and Clinical Haematology, Olivia Newton-John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationMedical School, University of Western Australia, Crawley, Western Australia, Australiaen
dc.identifier.affiliationDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationDepartment of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom-
dc.identifier.affiliationDepartment of Haematology, St Vincent's Hospital, Fitzroy, Victoria, Australiaen
dc.identifier.affiliationDepartment of Haematology, Royal Melbourne Hospital & Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationClinical Haematology, Monash Health and Monash University, Clayton, Victoria, Australia-
dc.identifier.affiliationCancer Care Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia-
dc.identifier.affiliationClinical Haematology, Monash Health and Monash University, Clayton, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia-
dc.identifier.affiliationDepartment of Haematology, Flinders Medical Centre, Bedford Park, South Australia, Australia-
dc.identifier.affiliationDepartment of Haematology, St Vincent's Hospital, Fitzroy, Victoria, Australia-
dc.identifier.affiliationDepartment of Haematology, Gold Coast University Hospital, Southport, Queensland, Australia-
dc.identifier.affiliationDepartment of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia-
dc.identifier.affiliationDepartment of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore-
dc.identifier.affiliationDepartment of Haematology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia-
dc.identifier.affiliationDepartment of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore-
dc.identifier.affiliationDepartment of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia-
dc.identifier.affiliationDepartment of Haematology, Gold Coast University Hospital, Southport, Queensland, Australia-
dc.identifier.affiliationDepartment of Haematology, Flinders Medical Centre, Bedford Park, South Australia, Australia-
dc.identifier.affiliationCancer Care Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia-
dc.identifier.affiliationClinical Haematology, Monash Health and Monash University, Clayton, Victoria, Australia-
dc.identifier.affiliationDepartment of Haematology, Royal Melbourne Hospital & Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1002/hon.2618-
dc.identifier.orcid0000-0001-5050-1223en
dc.identifier.orcid0000-0001-7988-1565en
dc.identifier.pubmedid30983008-
dc.type.austinJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.